<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnostic testing for toxoplasmosis infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnostic testing for toxoplasmosis infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnostic testing for toxoplasmosis infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph D Schwartzman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eskild Petersen, MD, DMSc, DTM&amp;H</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13029269"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Toxoplasmosis is a worldwide zoonosis caused by the intracellular protozoan parasite <em>Toxoplasma gondii</em> (<em>T. gondii</em>). Infection in humans most commonly occurs through the ingestion of raw or undercooked meat that contains tissue cysts, through ingestion of water or food contaminated with oocysts, or congenitally through transplacental transmission from a mother who acquired infection during pregnancy. Transmission has also been reported through solid organ transplantation.</p><p>Laboratory testing is usually necessary to establish the diagnosis of toxoplasmosis because the clinical manifestations of infection are so protean. The diagnostic methodology requires careful consideration based on the patient’s clinical presentation. Available diagnostic modalities for <em>T. gondii</em> include serologic assays, molecular-based techniques (eg, polymerase chain reaction-based assays), and histopathology.</p><p>This topic will address diagnostic techniques for toxoplasmosis in the immunocompetent and immunocompromised adult. Additional topic reviews that discuss toxoplasmosis include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/120887.html" rel="external">"Toxoplasmosis: Acute systemic disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5699.html" rel="external">"Toxoplasmosis: Ocular disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15835.html" rel="external">"Congenital toxoplasmosis: Treatment, outcome, and prevention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3718.html" rel="external">"Approach to the patient with HIV and central nervous system lesions"</a>.)</p><p></p><p class="headingAnchor" id="H640775507"><span class="h1">APPROACH TO DIAGNOSIS</span><span class="headingEndMark"> — </span>For patients with suspected toxoplasmosis, the approach to diagnosis depends upon the patient’s immune status and their clinical presentation. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>For immunocompetent patients with suspected acute infection, including pregnant women, serologic testing is typically used as the initial diagnostic step. For pregnant women, the use of reference laboratories and additional testing methods are often needed to avoid delays in diagnosis. (See <a class="local">'Serologic testing'</a> below and <a class="local">'Considerations in pregnant women'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with chorioretinitis, serology or aqueous humor analysis can be used to support the diagnosis. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5699.html" rel="external">"Toxoplasmosis: Ocular disease", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For immunocompromised patients with central nervous system (CNS) lesions, a definitive diagnosis requires a compatible clinical syndrome (eg, headache, neurologic symptoms, fever), identification of one or more mass lesions by brain imaging, and detection of toxoplasma DNA in cerebrospinal fluid or the presence of the organism in a biopsy specimen. However, in some cases, a presumptive diagnosis is made based upon the clinical presentation, and empiric treatment is administered. For such patients, response to therapy is supportive of the diagnosis. (See <a class="local">'Polymerase chain reaction assays'</a> below and <a class="local">'Histopathology'</a> below and  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV", section on 'Approach to diagnosis'</a>.)</p><p></p><p>Additional discussions of how to diagnose and treat toxoplasmosis are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/120887.html" rel="external">"Toxoplasmosis: Acute systemic disease", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/5699.html" rel="external">"Toxoplasmosis: Ocular disease", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Indications for maternal diagnostic testing'</a>.)</p><p class="headingAnchor" id="H5237544"><span class="h1">SEROLOGIC TESTING</span></p><p class="headingAnchor" id="H29313912"><span class="h2">Diagnosing acute infection</span><span class="headingEndMark"> — </span><em>T. gondii</em> infection can be diagnosed indirectly with serologic testing in patients with suspected acute disease (eg, fever and adenopathy), except in patients who are severely immunocompromised and may not be able to mount an antibody response [<a href="#rid1">1-13</a>]. The clinical manifestations of acute infection are described in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/120887.html" rel="external">"Toxoplasmosis: Acute systemic disease"</a>.)</p><p>In acute infection,<em> toxoplasma</em>-specific IgM antibodies usually appear within one week and continue to rise. The IgM titer subsequently declines and disappears, but the rate of decline is highly variable from individual to individual, and in some patients, may take months or longer [<a href="#rid2">2,3</a>]. <em>Toxoplasma</em>-specific IgG antibodies subsequently follow within approximately two weeks of primary infection, peak within approximately eight weeks, and generally persist for life. There is no direct correlation between the height of the IgG titer and the proximity of infection.</p><p class="headingAnchor" id="H1308280844"><span class="h3">Initial tests</span><span class="headingEndMark"> — </span>Enzyme-linked immunosorbent assays (ELISA) are typically used for detection of IgM and IgG antibodies [<a href="#rid2">2</a>]. Immunofluorescence antibody (IFA) tests can also be used, but are much less common. Some of these tests are available commercially, while others are only available in specialized research laboratories [<a href="#rid1">1,3-13</a>]. The performance of these tests varies. As an example, one study of six different IgG ELISA test kits found that the sensitivity ranged from 93 to 100 percent and the specificity ranged from 78 to 99 percent [<a href="#rid14">14</a>].</p><p>The Sabin-Feldman dye test, which only detects IgG antibody, was the reference gold standard for testing blood or cerebral spinal fluid (CSF) since 1948, but is now only available in certain reference laboratories, such as the Palo Alto Foundation [<a href="#rid6">6,15</a>].</p><p class="headingAnchor" id="H10843435"><span class="h3">Interpretation of initial results</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonreactive IgM</strong> – Acute toxoplasmosis is highly unlikely in a patient with signs of cervical lymphadenopathy who has a negative <em>Toxoplasma</em>-specific IgM antibody. However, if the test was obtained within one week of developing symptoms, and clinical suspicion remains high, the IgM should be repeated.</p><p></p><p class="bulletIndent1">False-negative serologic testing occurs rarely, and is typically seen in patients who have a primary immunodeficiency such as hypogammaglobulinemia, or among those who are significantly immunocompromised (eg, transplant patients, especially bone marrow transplants, or those with HIV infection) [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reactive IgM and nonreactive IgG</strong> – In a patient with signs and symptoms of primary toxoplasmosis, a reactive <em>Toxoplasma</em>-specific IgM antibody paired with a nonreactive IgG antibody is suggestive of acute infection. The diagnostic certainty increases if repeat testing demonstrates the appearance of <em>Toxoplasma</em>-specific IgG antibody. </p><p></p><p class="bulletIndent1">However, if the IgM antibody is positive two to three weeks later, but the IgG antibody remains negative, the initial IgM may be a false-positive. False-positive IgM antibody results are a significant issue in serologic testing for toxoplasmosis [<a href="#rid16">16</a>]. A false-positive IgM test result may be related to rheumatoid factor, antinuclear antibodies, and nonspecific binding in vitro [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">In settings where it is important to determine if the IgM is a true or false-positive result (eg, pregnancy), an IgM capture ELISA or IgM immunosorbent agglutination assay (ISAGA) should be performed. (See <a class="local">'Confirmatory IgM testing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reactive IgM and reactive IgG</strong> – In patients with acute infection, it is common to see a positive result for both IgM and IgG antibodies since the IgG antibody rises quickly after primary infection. However, clinicians should be aware that IgM antibodies can persist for months (or years) after primary infection [<a href="#rid3">3</a>]. Thus, a reactive IgM antibody test for toxoplasmosis must always be interpreted within the clinical context. Diagnostic confirmation can be pursued with an alternative method of diagnostic testing, such as avidity testing, especially if it is important to understand when the infection occurred (eg, pregnant women). (See <a class="local">'Avidity testing'</a> below.)</p><p></p><p class="headingAnchor" id="H1688715067"><span class="h3">Additional testing</span></p><p class="headingAnchor" id="H1073626670"><span class="h4">Confirmatory IgM testing</span><span class="headingEndMark"> — </span>Additional testing can be performed to confirm acute infection in patients with a positive IgM serology for toxoplasmosis if two samples taken two weeks apart do not confirm or refute acute infection [<a href="#rid2">2</a>]. (See <a class="local">'Interpretation of initial results'</a> above.)</p><p>For such patients, a confirmatory IgM capture ELISA or an IgM ISAGA can be performed since these tests are sensitive and specific for <em>Toxoplasma</em>-specific IgM antibodies. Some reference laboratories, such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sutterhealth.org%2Fpamf%2Fservices%2Flab-pathology%2Fserology-clinician-guide&amp;token=TsDnQOmikCvB1kBn4hkkLCiV1i%2FkbPpJvt3Sx%2FN28G6gU1SiMQKWSazFfSXn2JGNrFJuue%2FGTunIzK1aLgAwLG4srXxYvSWrNMeiV2mQClk%3D&amp;TOPIC_ID=14003" target="_blank">Jack S Remington Laboratory</a>, offer advice to clinicians regarding specimen handling and choice of testing.</p><p class="headingAnchor" id="H1207145758"><span class="h4">Avidity testing</span><span class="headingEndMark"> — </span>An assessment of the IgG antibody "avidity pattern" can be performed to help discriminate recently acquired IgG antibodies from antibodies formed in the past [<a href="#rid8">8-13,17-19</a>]. Avidity is measured by exposing an antigen-antibody complex to reagents that can lead to dissociation of the specific <em>Toxoplasma</em> IgG antibody from its antigen.</p><p>A high antibody avidity is seen during infection that is greater than four months old [<a href="#rid13">13,20,21</a>]. Thus, acute toxoplasmosis would be unlikely in an immunocompetent host with cervical lymphadenopathy and a high avidity test. In a comparative trial of four commercially available assays, the positive predictive value of a high-avidity result was 100 percent for latent infection versus acute disease (within four months) in immunocompetent, untreated individuals [<a href="#rid22">22</a>].</p><p>Low-avidity tests are less useful diagnostically. Although a low antibody avidity is typically seen in patients with recent infection (often within four months), in some cases low-avidity antibodies can persist for months. Thus, in situations where therapeutic decisions depend upon dating the infection (eg, pregnancy), a low-avidity antibody test is not diagnostic of acute disease without further testing (eg, agglutination assays and/or specific immunoglobulin tests) [<a href="#rid22">22,23</a>]. These adjunctive tests are available in the United States at the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.pamf.org%2Fserology%2Fclinicianguide.html&amp;token=oLXb6NSMOZdF35h7AB6nuRRNL9X%2FDm%2FisUNm19Floqxt4OMsEq%2FwBRD943lC%2BSYOS1LnNXWhssbg6jZpXZ53Ww%3D%3D&amp;TOPIC_ID=14003" target="_blank">Palo Alto Medical Foundation</a>. </p><p class="headingAnchor" id="H253179725"><span class="h4">Agglutination assays</span><span class="headingEndMark"> — </span>Agglutination tests can measure IgM and IgG antibodies [<a href="#rid24">24</a>]; these tests are only performed at the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.pamf.org%2Fserology%2Fclinicianguide.html&amp;token=oLXb6NSMOZdF35h7AB6nuRRNL9X%2FDm%2FisUNm19Floqxt4OMsEq%2FwBRD943lC%2BSYOS1LnNXWhssbg6jZpXZ53Ww%3D%3D&amp;TOPIC_ID=14003" target="_blank">Palo Alto Foundation</a> in the United States. </p><p>Various antibodies to <em>T. gondii</em> react differently when different fixatives (eg, acetone and formalin) are used to fix the parasites. As an example, early antibodies react to acetone-fixed parasites, while antibodies that develop later in infection react to formalin-fixed parasites [<a href="#rid25">25,26</a>]. These properties have been used to differentiate antibodies that are formed either acutely or later in infection. (See <a class="local">'Which tests should be performed'</a> below.)</p><p class="headingAnchor" id="H1451662449"><span class="h2">Reactivation infection</span><span class="headingEndMark"> — </span>In most patients with suspected reactivation disease, serum IgM antibodies are usually absent and serum IgG antibodies present. However, in immunocompromised patients, the absence of IgG antibodies does not completely exclude the diagnosis. </p><p>In a patient with signs and symptoms of reactivation disease, additional testing (eg, polymerase chain reaction testing, histopathology) may be needed to establish the diagnosis since a positive serum IgG alone cannot distinguish active from past infection. In addition, although central nervous system infection may be suggested by intrathecally produced IgG or IgM, CSF antibody tests can be confounded by contamination of the CSF by serum during the lumbar puncture, or passive transfer of antibody from the blood. </p><p>More detailed discussions of how to diagnose toxoplasmosis in patients with presumed reactivation disease are presented elsewhere. (See <a class="local">'Polymerase chain reaction assays'</a> below and <a class="local">'Histopathology'</a> below and  <a class="medical medical_review" href="/z/d/html/5699.html" rel="external">"Toxoplasmosis: Ocular disease", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV", section on 'Approach to diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H10843290"><span class="h1">POLYMERASE CHAIN REACTION ASSAYS</span><span class="headingEndMark"> — </span>Commercially available polymerase chain reaction (PCR) assays can detect parasite DNA in blood, cerebrospinal fluid, aqueous humor, and bronchoalveolar lavage fluid [<a href="#rid27">27,28</a>]. Although PCR testing is rarely performed in immunocompetent patients presenting with cervical lymphadenopathy [<a href="#rid2">2</a>], it can be a helpful aid in diagnosing immunocompetent patients with ocular disease and immunocompromised hosts with suspected central nervous system, pulmonary, or disseminated disease. (See  <a class="medical medical_review" href="/z/d/html/5699.html" rel="external">"Toxoplasmosis: Ocular disease", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Pulmonary infections'</a>.)</p><p>Since there is no standardized PCR assay, the sensitivity of PCR assays varies widely (from 15 to 85 percent for blood), although specificity appears to be high (greater than 95 percent) [<a href="#rid29">29</a>]. A comparison of DNA targets found that a repeated sequence (Rep-529) was superior in sensitivity to another common target sequence (B1); thus, Rep-529 is recommended for standardization of the PCR assay [<a href="#rid30">30</a>].</p><p>The use of PCR testing to diagnose fetal infection is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Diagnostic testing (PCR) and performance'</a>.)</p><p class="headingAnchor" id="H5237302"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span><em>Toxoplasma</em> may be detected on histopathology in one of two forms: tachyzoites or cysts. Tachyzoites are crescent-shaped and usually establish the diagnosis of acute infection [<a href="#rid3">3</a>]. Cysts are circular in shape and may represent latent infection or reactivation disease, depending on the host [<a href="#rid31">31</a>]. Images of cysts and tachyzoites can be found at the United States Centers for Disease Control and Prevention <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fdpdx%2Ftoxoplasmosis%2Findex.html&amp;token=Ytu4OABK8KmAewmODlXE4060a92Pdz3P%2BANN%2FxOPKWsUmrDfNc9qR%2FuxcArVk26%2Bav9YrsB4J4lXygXTgWlJ4w%3D%3D&amp;TOPIC_ID=14003" target="_blank">website</a>.</p><p>Specimens of tissue, blood, sputum, amniotic fluid, centrifuged cerebrospinal fluid, or brain tissue are stained with standard histologic dyes, such as hematoxylin and eosin, Wright’s, or Giemsa [<a href="#rid4">4,32</a>]. The sensitivity and specificity of these standard staining techniques for <em>T. gondii</em> is not well established. It is generally thought that immunohistochemistry, with the use of specific anti-<em>Toxoplasma</em> antibody, or immunoperoxidase tests, which use antisera to <em>T. gondii</em>, are more sensitive and specific than routine staining techniques and may be particularly helpful for the examination of necrotic tissue [<a href="#rid33">33</a>].</p><p>Parasites are rarely detected by histopathology in lymphadenitis, but the histopathologic pattern may suggest a diagnosis of toxoplasmosis [<a href="#rid31">31,34,35</a>]. For example, a pattern of reactive follicular hyperplasia, clusters of epithelioid histiocytes, and sinusoidal distention with monocytoid B cells would be indicative of toxoplasmosis and not malignancy.</p><p class="headingAnchor" id="H2327541063"><span class="h1">CONSIDERATIONS IN PREGNANT WOMEN</span><span class="headingEndMark"> — </span>The key diagnostic consideration in pregnant women is to determine whether acute infection occurred during pregnancy and thus could be transmitted to the fetus. </p><p class="headingAnchor" id="H1669675815"><span class="h2">When testing should be performed</span><span class="headingEndMark"> — </span>Serologic testing for toxoplasmosis should be performed if there is clinical suspicion of acute toxoplasmosis during pregnancy, such as [<a href="#rid36">36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Ultrasonographic abnormalities in the fetus that suggest congenital toxoplasmosis (eg, intracranial hyperechogenic foci or calcifications and/or cerebral ventricular dilatation). (See  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Ultrasound findings in congenital toxoplasmosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A high clinical suspicion of acute infection in the mother based upon symptoms (eg, fever and adenopathy). (See  <a class="medical medical_review" href="/z/d/html/120887.html" rel="external">"Toxoplasmosis: Acute systemic disease"</a>.) </p><p></p><p>In some countries (eg, France, Austria), serial serologic screening for toxoplasmosis is performed. A discussion of screening in pregnancy is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Should all pregnant individuals be screened?'</a> and  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Indications for maternal diagnostic testing'</a>.)</p><p class="headingAnchor" id="H3596411846"><span class="h2">Which tests should be performed</span><span class="headingEndMark"> — </span>It is important to make the diagnosis of toxoplasmosis as soon as possible in pregnant women suspected of having acute infection so treatment to prevent congenital infection can be initiated. (See  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Approach to maternal treatment for reduction of congenital toxoplasmosis'</a> and  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Efficacy'</a>.)</p><p>If possible, initial testing should be sent to a reference laboratory to avoid delays in diagnosis. Testing panels that have a specificity of 100 percent are available, reducing the risk of a false-positive test. </p><p>If initial testing is sent to a commercial laboratory, confirmatory testing should be sent to a reference laboratory if the IgM is positive or equivocal (regardless of the IgG). If the IgM is negative and the IgG is positive, the American Academy of Pediatrics suggests that confirmatory testing be performed in women &gt;20 weeks gestation or if there is a high clinical suspicion of congenital toxoplasmosis (ie, abnormal ultrasound) [<a href="#rid36">36</a>].</p><p>In the United States, the reference laboratory is the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.pamf.org%2Fserology%2Fclinicianguide.html&amp;token=oLXb6NSMOZdF35h7AB6nuRRNL9X%2FDm%2FisUNm19Floqxt4OMsEq%2FwBRD943lC%2BSYOS1LnNXWhssbg6jZpXZ53Ww%3D%3D&amp;TOPIC_ID=14003" target="_blank">Palo Alto Medical Foundation</a>, and the specific panel depends upon the gestational age [<a href="#rid36">36</a>]. As an example, for women ≤16 weeks, the testing panel includes the <em>Toxoplasma</em> IgG dye test, the <em>Toxoplasma</em> IgM enzyme-linked immunosorbent assay (ELISA), and the <em>Toxoplasma</em> IgG avidity test. Avidity testing is used in this setting since a high-avidity test is seen during infection that is greater than four months old (ie, it can exclude infection acquired during pregnancy or close to conception). By contrast, for women &gt;16 weeks gestational age, the panel includes the differential agglutination test (also known as the "AC/HS test") instead of the avidity test. An acute AC/HS typically indicates infection acquired &lt;12 months from the time of testing, and a nonacute AC/HS indicates infection acquired ≥12 months from the time of testing (ie, infection was acquired before conception).</p><p>Outside of the United States, other serologic testing panels may be used. As an example, a standard ELISA-IgG test may be performed as part of the initial testing panel rather than a dye test, and an IgG-avidity assay (rather than the AC/HS test) may be used even in women &gt;16 weeks gestation. </p><p>Information on testing for fetal infection is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Fetal infection'</a>.) </p><p class="headingAnchor" id="H2167195714"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113063.html" rel="external">"Society guideline links: Toxoplasmosis"</a>.)</p><p class="headingAnchor" id="H5238681"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Toxoplasmosis is a worldwide zoonosis caused by the intracellular protozoan parasite <em>Toxoplasma gondii</em>. Laboratory testing is usually necessary to establish the diagnosis of toxoplasmosis because the clinical manifestations of infection are so protean. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>T. gondii</em> infection can be diagnosed indirectly with serologic testing (eg, enzyme-linked immunosorbent assays). In acute infection, <em>Toxoplasma</em>-specific IgM antibodies usually appear within one week and continue to rise. The IgM titer subsequently declines and disappears, but the rate of decline is highly variable. <em>Toxoplasma</em>-specific IgG antibodies subsequently follow within approximately two weeks of primary infection, peak within approximately eight weeks, and generally persist for life. (See <a class="local">'Diagnosing acute infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a patient with symptoms and signs of primary toxoplasmosis, acute toxoplasmosis is unlikely in the setting of a negative <em>Toxoplasma</em>-specific IgM. By contrast, a reactive <em>Toxoplasma</em>-specific IgM antibody paired with a nonreactive IgG antibody would be suggestive of acute infection. The diagnostic certainty increases if repeat testing demonstrates the appearance of <em>Toxoplasma</em>-specific IgG antibody, since false-positive IgM tests can occur. (See <a class="local">'Interpretation of initial results'</a> above and <a class="local">'Confirmatory IgM testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In clinical practice, a positive result for both IgM and IgG antibodies can be seen in the setting of acute infection. However, clinicians should be aware that IgM antibodies can persist for months (or years) after primary infection. Thus, a reactive IgM antibody test for toxoplasmosis must always be interpreted within the clinical context. An assessment of the IgG antibody "avidity pattern" can be performed to help discriminate recently acquired IgG antibodies from antibodies formed in the past. (See <a class="local">'Interpretation of initial results'</a> above and <a class="local">'Avidity testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with suspected reactivation disease typically have IgG antibodies present, although additional testing (eg, polymerase chain reaction testing, histopathology) may be needed to establish the diagnosis since a positive serum IgG alone cannot distinguish active from past infection. In addition, the absence of antibodies in immunocompromised patients does not completely exclude the possibility of reactivation disease. (See <a class="local">'Reactivation infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polymerase chain reaction (PCR) testing can be a helpful aid in diagnosing toxoplasmosis in immunocompromised hosts with suspected disseminated disease, or in patients with ocular disease. However, PCR is rarely performed in immunocompetent patients presenting with cervical lymphadenopathy. (See <a class="local">'Polymerase chain reaction assays'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Toxoplasma</em> may be detected on histopathology in one of two forms: tachyzoites or cysts. Tachyzoites are crescent-shaped and usually establish the diagnosis of acute infection. Cysts are circular in shape and may represent latent infection or reactivation disease, depending on the host. (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The key diagnostic consideration in pregnant women is to determine whether acute infection occurred during pregnancy and, therefore, could have been transmitted to the fetus. (See <a class="local">'Considerations in pregnant women'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Montoya JG, Remington JS. Studies on the serodiagnosis of toxoplasmic lymphadenitis. Clin Infect Dis 1995; 20:781.</a></li><li><a class="nounderline abstract_t">Montoya JG. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis 2002; 185 Suppl 1:S73.</a></li><li><a class="nounderline abstract_t">Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363:1965.</a></li><li class="breakAll">Garcia LS, Bruckner DA. Tissue protozoa. In: Diagnostic Medical Parasitology, Third Edition, ASM Press, Washington, DC 1997. p.111.</li><li class="breakAll">Remington JS, McLeod R, Desmonts G. Toxoplasmosis. In: Infectious Diseases of the Fetus and Newborn Infant, Fourth Edition, Remington JS, Klein JO (Eds), WB Saunders, Philadelphia 1995. p.140.</li><li><a class="nounderline abstract_t">Sabin AB, Feldman HA. Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoon Parasite (Toxoplasma). Science 1948; 108:660.</a></li><li><a class="nounderline abstract_t">Walton BC, Benchoff BM, Brooks WH. Comparison of the indirect fluorescent antibody test and methylene blue dye test for detection of antibodies to Toxoplasma gondii. Am J Trop Med Hyg 1966; 15:149.</a></li><li><a class="nounderline abstract_t">Roos T, Martius J, Gross U, Schrod L. Systematic serologic screening for toxoplasmosis in pregnancy. Obstet Gynecol 1993; 81:243.</a></li><li><a class="nounderline abstract_t">Skinner LJ, Chatterton JM, Joss AW, et al. The use of an IgM immunosorbent agglutination assay to diagnose congenital toxoplasmosis. J Med Microbiol 1989; 28:125.</a></li><li><a class="nounderline abstract_t">Naot Y, Desmonts G, Remington JS. IgM enzyme-linked immunosorbent assay test for the diagnosis of congenital Toxoplasma infection. J Pediatr 1981; 98:32.</a></li><li><a class="nounderline abstract_t">Verhofstede C, Van Renterghem L, Plum J. Comparison of six commercial enzyme linked immunosorbent assays for detecting IgM antibodies against Toxoplasma gondii. J Clin Pathol 1989; 42:1285.</a></li><li><a class="nounderline abstract_t">Hsu HW, Grady GF, Maguire JH, et al. Newborn screening for congenital Toxoplasma infection: five years experience in Massachusetts, USA. Scand J Infect Dis Suppl 1992; 84:59.</a></li><li><a class="nounderline abstract_t">Lappalainen M, Koskela P, Koskiniemi M, et al. Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG. J Infect Dis 1993; 167:691.</a></li><li><a class="nounderline abstract_t">Wilson M, Remington JS, Clavet C, et al. Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group. J Clin Microbiol 1997; 35:3112.</a></li><li><a class="nounderline abstract_t">Kaiser K, Van Loon AM, Pelloux H, et al. Multicenter proficiency study for detection of Toxoplasma gondii in amniotic fluid by nucleic acid amplification methods. Clin Chim Acta 2007; 375:99.</a></li><li><a class="nounderline abstract_t">Liesenfeld O, Press C, Montoya JG, et al. False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test. J Clin Microbiol 1997; 35:174.</a></li><li><a class="nounderline abstract_t">Naot Y, Remington JS. An enzyme-linked immunosorbent assay for detection of IgM antibodies to Toxoplasma gondii: use for diagnosis of acute acquired toxoplasmosis. J Infect Dis 1980; 142:757.</a></li><li><a class="nounderline abstract_t">Hedman K, Lappalainen M, Seppäiä I, Mäkelä O. Recent primary toxoplasma infection indicated by a low avidity of specific IgG. J Infect Dis 1989; 159:736.</a></li><li><a class="nounderline abstract_t">Bobic B, Klun I, Vujanic M, et al. Comparative evaluation of three commercial Toxoplasma-specific IgG antibody avidity tests and significance in different clinical settings. J Med Microbiol 2009; 58:358.</a></li><li><a class="nounderline abstract_t">Jenum PA, Stray-Pedersen B, Gundersen AG. Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity. J Clin Microbiol 1997; 35:1972.</a></li><li><a class="nounderline abstract_t">Beghetto E, Buffolano W, Spadoni A, et al. Use of an immunoglobulin G avidity assay based on recombinant antigens for diagnosis of primary Toxoplasma gondii infection during pregnancy. J Clin Microbiol 2003; 41:5414.</a></li><li><a class="nounderline abstract_t">Villard O, Breit L, Cimon B, et al. Comparison of four commercially available avidity tests for Toxoplasma gondii-specific IgG antibodies. Clin Vaccine Immunol 2013; 20:197.</a></li><li><a class="nounderline abstract_t">Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev 2012; 25:264.</a></li><li><a class="nounderline abstract_t">Dannemann BR, Vaughan WC, Thulliez P, Remington JS. Differential agglutination test for diagnosis of recently acquired infection with Toxoplasma gondii. J Clin Microbiol 1990; 28:1928.</a></li><li><a class="nounderline abstract_t">Remington JS, Thulliez P, Montoya JG. Recent developments for diagnosis of toxoplasmosis. J Clin Microbiol 2004; 42:941.</a></li><li><a class="nounderline abstract_t">Montoya JG, Berry A, Rosso F, Remington JS. The differential agglutination test as a diagnostic aid in cases of toxoplasmic lymphadenitis. J Clin Microbiol 2007; 45:1463.</a></li><li><a class="nounderline abstract_t">Dupouy-Camet J, de Souza SL, Maslo C, et al. Detection of Toxoplasma gondii in venous blood from AIDS patients by polymerase chain reaction. J Clin Microbiol 1993; 31:1866.</a></li><li><a class="nounderline abstract_t">Mele A, Paterson PJ, Prentice HG, et al. Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature. Bone Marrow Transplant 2002; 29:691.</a></li><li><a class="nounderline abstract_t">Bastien P. Molecular diagnosis of toxoplasmosis. Trans R Soc Trop Med Hyg 2002; 96 Suppl 1:S205.</a></li><li><a class="nounderline abstract_t">Belaz S, Gangneux JP, Dupretz P, et al. A 10-year retrospective comparison of two target sequences, REP-529 and B1, for Toxoplasma gondii detection by quantitative PCR. J Clin Microbiol 2015; 53:1294.</a></li><li class="breakAll">Frenkel JK. Toxoplasmosis. In: Pathology of Infectious Diseases, Connor DH, Chandler FW, Schwartz DA, et al (Eds), Appleton &amp; Lange, Stamford, CT 1997. p.1261.</li><li><a class="nounderline abstract_t">Laibe S, Ranque S, Curtillet C, et al. Timely diagnosis of disseminated toxoplasmosis by sputum examination. J Clin Microbiol 2006; 44:646.</a></li><li><a class="nounderline abstract_t">Conley FK, Jenkins KA, Remington JS. Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum Pathol 1981; 12:690.</a></li><li><a class="nounderline abstract_t">McCabe RE, Brooks RG, Dorfman RF, Remington JS. Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy. Rev Infect Dis 1987; 9:754.</a></li><li><a class="nounderline abstract_t">Eapen M, Mathew CF, Aravindan KP. Evidence based criteria for the histopathological diagnosis of toxoplasmic lymphadenopathy. J Clin Pathol 2005; 58:1143.</a></li><li><a class="nounderline abstract_t">Maldonado YA, Read JS, COMMITTEE ON INFECTIOUS DISEASES. Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. Pediatrics 2017; 139.</a></li></ol></div><div id="topicVersionRevision">Topic 14003 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7795074" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Studies on the serodiagnosis of toxoplasmic lymphadenitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11865443" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15194258" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15194258" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15194258" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17744024" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoon Parasite (Toxoplasma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4160144" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparison of the indirect fluorescent antibody test and methylene blue dye test for detection of antibodies to Toxoplasma gondii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8423959" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Systematic serologic screening for toxoplasmosis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2644432" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The use of an IgM immunosorbent agglutination assay to diagnose congenital toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7452400" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : IgM enzyme-linked immunosorbent assay test for the diagnosis of congenital Toxoplasma infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2613922" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comparison of six commercial enzyme linked immunosorbent assays for detecting IgM antibodies against Toxoplasma gondii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1290076" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Newborn screening for congenital Toxoplasma infection: five years experience in Massachusetts, USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8440939" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399504" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16860303" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Multicenter proficiency study for detection of Toxoplasma gondii in amniotic fluid by nucleic acid amplification methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8968902" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7007520" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : An enzyme-linked immunosorbent assay for detection of IgM antibodies to Toxoplasma gondii: use for diagnosis of acute acquired toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2926163" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Recent primary toxoplasma infection indicated by a low avidity of specific IgG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19208887" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparative evaluation of three commercial Toxoplasma-specific IgG antibody avidity tests and significance in different clinical settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9230365" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14662919" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Use of an immunoglobulin G avidity assay based on recombinant antigens for diagnosis of primary Toxoplasma gondii infection during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23239801" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparison of four commercially available avidity tests for Toxoplasma gondii-specific IgG antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491772" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Epidemiology of and diagnostic strategies for toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2229374" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Differential agglutination test for diagnosis of recently acquired infection with Toxoplasma gondii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15004036" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Recent developments for diagnosis of toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17314220" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The differential agglutination test as a diagnostic aid in cases of toxoplasmic lymphadenitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8349765" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Detection of Toxoplasma gondii in venous blood from AIDS patients by polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12180115" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12055840" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Molecular diagnosis of toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25653416" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A 10-year retrospective comparison of two target sequences, REP-529 and B1, for Toxoplasma gondii detection by quantitative PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25653416" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A 10-year retrospective comparison of two target sequences, REP-529 and B1, for Toxoplasma gondii detection by quantitative PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16455936" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Timely diagnosis of disseminated toxoplasmosis by sputum examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7026410" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3326123" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254101" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Evidence based criteria for the histopathological diagnosis of toxoplasmic lymphadenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28138010" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
